Stock Scorecard
Stock Summary for Biogen Inc (BIIB) - $202.90 as of 4/25/2024 7:30:41 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BIIB
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BIIB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BIIB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for BIIB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for BIIB
Financial Details for BIIB
Company Overview |
|
|---|---|
| Ticker | BIIB |
| Company Name | Biogen Inc |
| Country | USA |
| Description | Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 4/24/2024 |
Stock Price History |
|
| Last Day Price | 202.90 |
| Last Day Price Updated | 4/25/2024 7:30:41 PM EST |
| Last Day Volume | 3,265,676 |
| Average Daily Volume | 1,299,908 |
| 52-Week High | 319.76 |
| 52-Week Low | 189.44 |
| Last Price to 52 Week Low | 7.11% |
Valuation Measures |
|
| Trailing PE | 24.21 |
| Industry PE | 61.03 |
| Sector PE | 61.73 |
| 5-Year Average PE | 10.43 |
| Free Cash Flow Ratio | 28.70 |
| Industry Free Cash Flow Ratio | 18.94 |
| Sector Free Cash Flow Ratio | 30.74 |
| Current Ratio Most Recent Quarter | 2.00 |
| Total Cash Per Share | 7.07 |
| Book Value Per Share Most Recent Quarter | 102.14 |
| Price to Book Ratio | 1.95 |
| Industry Price to Book Ratio | 7.50 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 2.93 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.51 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 145,361,000 |
| Market Capitalization | 29,493,746,900 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.71% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -54.90% |
| Annual Earnings Growth | -61.89% |
| Reported EPS 12 Trailing Months | 7.98 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 15.08 |
| Net Income Twelve Trailing Months | 1,161,100,000 |
| Net Income Past Year | 1,161,100,000 |
| Net Income Prior Year | 3,046,900,000 |
| Quarterly Revenue Growth YOY | -6.20% |
| 5-Year Revenue Growth | -6.07% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,027,500,000 |
| Total Cash Past Year | 1,027,500,000 |
| Total Cash Prior Year | 5,112,200,000 |
| Net Cash Position Most Recent Quarter | -5,910,700,000 |
| Net Cash Position Past Year | -5,910,700,000 |
| Long Term Debt Past Year | 6,938,200,000 |
| Long Term Debt Prior Year | 6,281,000,000 |
| Total Debt Most Recent Quarter | 6,938,200,000 |
| Equity to Debt Ratio Past Year | 0.68 |
| Equity to Debt Ratio Most Recent Quarter | 0.68 |
| Total Stockholder Equity Past Year | 14,799,400,000 |
| Total Stockholder Equity Prior Year | 13,397,900,000 |
| Total Stockholder Equity Most Recent Quarter | 14,799,400,000 |
Options |
|
| Put/Call Ratio | 1.23 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -5.85 |
| MACD Signal | -6.43 |
| 20-Day Bollinger Lower Band | 188.36 |
| 20-Day Bollinger Middle Band | 229.44 |
| 20-Day Bollinger Upper Band | 270.53 |
| Beta | -0.01 |
| RSI | 44.37 |
| 50-Day SMA | 253.33 |
| 200-Day SMA | 260.89 |
System |
|
| Modified | 4/24/2024 7:23:55 PM EST |